Key Highlights

  • CMPS shares are trading up 7.35% to $14.25.
  • The gain comes alongside a broad, sector-wide surge in biotechnology stocks, with peers Roivant Sciences (NASDAQ:ROIV), up 17.7%, and Soleno Therapeutics (NASDAQ:SLNC), up 10%, also posting sharp gains despite limited company-specific news.
  • The company reaffirmed plans for an FDA NDA submission for COMP360 psilocybin in the fourth quarter of 2026, following durable 26-week efficacy data.
  • Compass announced new participation at Psych Congress 2026, running September 14 to 19, where it will debut a new U.S. healthcare-provider education campaign.
  • The company also plans to present new health Economics and outcomes research and encore COMP360 data at the conference.

Shares Rally Alongside a Broad Biotech Surge

Compass Pathways (NASDAQ:CMPS) shares are rallying alongside a broad, sector-wide surge in biotechnology stocks, with peers including Roivant Sciences (NASDAQ:ROIV), up 17.7%, and Soleno Therapeutics (NASDAQ:SLNC), up 10%, also posting sharp gains despite limited company-specific news across the sector today. Compass is a clinical-stage biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health care.

COMP360 Filing Timeline Remains on Track

Investors continue to track the company's late-stage progress with COMP360, its proprietary high-purity synthetic psilocybin formulation for treatment-resistant depression, with Compass reaffirming plans for an FDA NDA submission in the fourth quarter of 2026 following durable 26-week efficacy data. COMP360 has received FDA Breakthrough Therapy Designation for treatment-resistant depression and is administered alongside structured psychological support.

New Conference Participation Keeps the Stock in Focus

The company also announced new participation at Psych Congress 2026, running September 14 to 19, where it will debut a new U.S. healthcare-provider education campaign and present new health economics and outcomes research alongside encore COMP360 data. Those developments keep the stock in focus ahead of its anticipated regulatory filing.

Filing and Launch Timeline in View

Compass Pathways shares are climbing as investors weigh both the sector-wide rally and the company's steady progress toward its anticipated NDA submission and potential first-half 2027 launch. Continued execution on the Q4 2026 filing timeline will likely remain the key catalyst for the stock going forward.